Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 14, 795 (2008)
doi:10.1038/nm0808-795b
National Cancer Institute helps businesses cross 'the valley of death'
Prashant Nair1
- Boston
The San Diego–based biotechnology firm NovaRx develops new cancer therapeutics, including experimental approaches involving vaccines. Like many other small companies, NovaRx faces a funding hurdle in advancing drugs from its pipeline into human clinical trials, says executive vice-chairman Habib Fakhrai.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
